791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Maxwell Wang, Baiyong Li, Yu Xia, Jun Zhu

Open source

DOI: 10.1136/jitc-2020-sitc2020.0791
Published: 2020-11
Container: Late-breaking abstracts
Publisher: BMJ Publishing Group Ltd
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2020-sitc2020.0791,
  title = {791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)},
  author = {Yuqin Song and Keshu Zhou and Chuan Jin and Zhengzi Qian and Ming Hou and Lei Fan and Fei Li and Kaiyang Ding and Hui Zhou and Xiaoling Li and Bing Chen and Xiuhua Sun and Xianmin Song and Ming Jiang and Qingyuan Zhang and Lihong Liu and Guohua Yu and Yu Hu and Zheng Zhao and Ligen Liu and Hongwei Xue and Jun Luo and Bai He and Xiaoping Jin and Maxwell Wang and Baiyong Li and Yu Xia and Jun Zhu},
  year = {2020},
  journal = {Late-breaking abstracts},
  doi = {10.1136/jitc-2020-sitc2020.0791},
  url = {https://doi.org/10.1136/jitc-2020-sitc2020.0791}
}

RIS

TY  - JOUR
TI  - 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)
AU  - Yuqin Song
AU  - Keshu Zhou
AU  - Chuan Jin
AU  - Zhengzi Qian
AU  - Ming Hou
AU  - Lei Fan
AU  - Fei Li
AU  - Kaiyang Ding
AU  - Hui Zhou
AU  - Xiaoling Li
AU  - Bing Chen
AU  - Xiuhua Sun
AU  - Xianmin Song
AU  - Ming Jiang
AU  - Qingyuan Zhang
AU  - Lihong Liu
AU  - Guohua Yu
AU  - Yu Hu
AU  - Zheng Zhao
AU  - Ligen Liu
AU  - Hongwei Xue
AU  - Jun Luo
AU  - Bai He
AU  - Xiaoping Jin
AU  - Maxwell Wang
AU  - Baiyong Li
AU  - Yu Xia
AU  - Jun Zhu
PY  - 2020
JO  - Late-breaking abstracts
DO  - 10.1136/jitc-2020-sitc2020.0791
UR  - https://doi.org/10.1136/jitc-2020-sitc2020.0791
ER  -

APA

Song, Y., Zhou, K., Jin, C., Qian, Z., Hou, M., Fan, L., Li, F., Ding, K., Zhou, H., Li, X., Chen, B., Sun, X., Song, X., Jiang, M., Zhang, Q., Liu, L., Yu, G., Hu, Y., Zhao, Z., Liu, L., Xue, H., Luo, J., He, B., Jin, X., Wang, M., Li, B., Xia, Y., & Zhu, J. (2020). 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL). Late-breaking abstracts. https://doi.org/10.1136/jitc-2020-sitc2020.0791

Source records

crossref · retrieved 2026-09-26T21:47:32.765Z